Main Uses and Therapeutic Intent

Betoftan is an ophthalmic solution containing betaxolol, a selective beta-1 adrenergic receptor blocker. It is primarily used to manage conditions characterized by increased intraocular pressure (IOP). By lowering the pressure within the eye, the medication helps prevent damage to the optic nerve and assists in the long-term management of visual function.

The medication is typically indicated for:

• Ocular Hypertension: A condition where the fluid pressure inside the eye is higher than the normal range, increasing the risk of developing glaucoma.
• Chronic Open-Angle Glaucoma: A progressive eye disease where the drainage angle of the eye remains open, but fluid does not drain properly, leading to a gradual increase in pressure.

Mechanism of Action and Benefits

Betoftan works by reducing the production of aqueous humor, the clear fluid found in the front part of the eye. When less fluid is produced, the internal pressure of the eye decreases.

Key Benefits

• Targeted Pressure Reduction: Effectively lowers elevated intraocular pressure, which is the primary modifiable risk factor in the progression of glaucoma.
• Selectivity: As a cardioselective beta-blocker, it specifically targets beta-1 receptors. This selectivity is intended to minimize the impact on respiratory function compared to non-selective ophthalmic beta-blockers.
• Neuroprotective Potential: Some clinical observations suggest that betaxolol may help maintain blood flow to the optic nerve, providing a supportive environment for retinal cells beyond the simple reduction of pressure.
• Suitability for Long-term Use: It is designed for the chronic management of eye pressure, helping to stabilize the condition over extended periods.

The eligibility profile for Бетофтан (Betaxolol ophthalmic solution) is defined by official regulatory documents, primarily restricting use based on cardiovascular and respiratory health.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults (including the elderly) and Pediatric patients where safety and effectiveness are established.
Populations for whom use is contraindicated	Patients with known hypersensitivity to the drug or any component, sinus bradycardia, atrioventricular (AV) block greater than first degree, overt cardiac failure, cardiogenic shock, or severe asthma/COPD.
Age-related eligibility rules	Use is established in adults and the elderly with no demonstrated geriatric-specific issues. Use is also established in pediatric patients.
Condition-specific eligibility rules	Caution is required for patients with a history of cardiac failure, heart block, certain vascular disorders, diabetes mellitus (due to the potential to mask hypoglycemia signs), and thyrotoxicosis.
Pregnancy and lactation eligibility status	Pregnancy is generally not recommended unless necessary, and the neonate must be monitored if used near delivery. Use during lactation may be permitted with caution, as systemic absorption is low.

Regulatory documents define eligibility by establishing absolute contraindications for severe cardiac and respiratory conditions, thus excluding a clearly defined non-eligible population. The profile confirms that use is established across broad age groups. Other medical conditions only result in restricted use where special caution and monitoring are required to prevent potential complications.

The interaction profile for Бетофтан is primarily defined by the systemic absorption of its active ingredient, Betaxolol, a beta-adrenergic receptor inhibitor. This absorption creates a potential for additive systemic effects when co-administered with other medications affecting the cardiovascular system, which is explicitly documented in official regulatory labeling.

Interaction Category	Documented Interaction Statement
Systemic PD Effects	Potential for additive effects resulting in hypotension (low blood pressure) and/or bradycardia (slow heart rate) with oral beta-adrenergic receptor inhibitors, Calcium Antagonists, Antiarrhythmics, or Catecholamine-Depleting Drugs (e.g., Reserpine).
Topical Restriction	Co-administration with other Topical beta-Adrenergic Blocking Agents is not recommended.
Timing Requirement	Must be administered at least 10 minutes apart from any other topical ophthalmic medicinal products.

Official documents note that beta-adrenergic receptor inhibitor activity may mask the clinical signs of acute hypoglycemia in diabetic patients or certain symptoms of hyperthyroidism, such as tachycardia. Furthermore, while official labeling mandates close observation for cardiovascular risks with various medicinal products, no known interactions with food, alcohol, or herbal products are explicitly documented.

Blocking the boldsymbolbeta1 Signal

The drug acts as a selective beta1-adrenergic receptor antagonist, engaging primarily with these receptors on the ciliary epithelium of the eye. This antagonistic interaction prevents natural signaling molecules, such as norepinephrine, from activating the receptor. This action initiates the drug's mechanism by reducing the molecular signal that would otherwise increase fluid production.

---

Pathway Cascade and Physiological Effect

The reduction in beta1 receptor activation leads to the inhibition of the associated adenylate cyclase enzyme, resulting in a lower intracellular concentration of the secondary messenger, cAMP. This molecular change results in a reduced rate of aqueous humor secretion by the ciliary epithelial cells. The physical consequence of inhibiting fluid production is a decrease in the volume of fluid inside the eye's anterior and posterior chambers, which in turn leads to a decrease in the intraocular pressure (IOP).

Additionally, the mechanism is associated with properties that include neural membrane stabilization, which influences cellular responses to certain stressors.

Betaxolol ophthalmic solution is typically used to treat open-angle glaucoma and ocular hypertension by lowering increased pressure within the eye. The medicine is usually administered as one drop in the affected eye(s) twice daily or as otherwise directed by a healthcare professional. It is important to follow the prescribed dosage and schedule precisely, as Betaxolol is used to control the condition, not cure it.

Administration Instructions

To ensure proper use and prevent contamination, follow these steps during application:

• Hand Hygiene: Always wash your hands thoroughly with soap and water before handling the eye drops.
• Preparation: If using the suspension form, shake the bottle well just before each use. Check the dropper tip to ensure it is not cracked or chipped.
• Instillation: Tilt your head back and gently pull down the lower eyelid to create a small pocket. Hold the bottle upside down, positioning the tip close to the eye without touching the tip to the eye, eyelid, or any other surface. Squeeze the bottle gently to release one drop into the pocket.
• Absorption: Immediately after instilling the drop, gently close your eye (do not blink or squeeze the eyelid) and apply light pressure with your finger to the inner corner of the eye, near the nose, for one to two minutes. This helps the medication absorb locally and reduces systemic absorption.
• Repeat: If applying to the second eye, repeat the steps.

Important Considerations

If you use other topical eye medications, wait at least five to ten minutes between administrations to prevent the second medication from washing out the first. If you wear contact lenses, remove them before instilling the drops and wait at least 15 minutes before reinserting them, as the preservative (benzalkonium chloride) may discolor soft contact lenses. If a dose is missed, apply it as soon as you remember; however, if it is almost time for the next dose, skip the missed one and continue with the regular schedule. Never use a double dose to compensate for a missed dose.

Research evidence / Overview of studies for Бетофтан

Evidence for Use in Elevated Eye Pressure and Glaucoma

Research examined Бетофтан (Betaxolol ophthalmic solution) primarily through Randomized Controlled Trials (RCTs) and Systematic Reviews to explore how symptoms change over time in adults with elevated Intraocular Pressure (IOP), Ocular Hypertension, and Chronic Open-Angle Glaucoma. Studies explored the use of the eye drops over short-term intervals, often comparing its effects to a placebo or other active treatments. The main focus was on the measurement of changes in the biomarker, Intraocular Pressure (IOP), inside the eye.

The findings from these studies consistently describe patterns related to changes observed in Intraocular Pressure (IOP) measurements across the observed populations. Research highlights these changes measured in this pressure biomarker across the observed groups. This evidence contributes to the broader landscape of how pressure is managed in conditions marked by functional limitations like glaucoma.

However, the existing studies provide limited insight into the long-term, functional outcomes reflecting daily functioning. While the pressure change was observed, the certainty remains low regarding the direct correlation between this measured IOP change and the long-term functional visual outcomes. Furthermore, the data from studies that examined comparisons of Betaxolol to other antiglaucoma treatments suggests mixed findings.

---

Studies Observing Long-Term Patterns and Follow-up

Research has also explored how the measured changes were maintained in long-term observational studies, with some patients being observed for periods lasting up to several years. These studies were applied in research contexts involving fluctuating or unstable symptoms, examining the consistency of the pressure changes over extended periods.

Studies reported patterns of pressure change that were tracked in the observed populations over these long-term intervals. In addition to measuring IOP, research examined outcomes related to systemic or functional imbalance, such as the rate at which ocular hypertension converted into established glaucoma, and the stability of the Optic Nerve Head.

---

Key Studies & References

1. DailyMed: Betaxolol Ophthalmic Solution (NDA 019845)
2. MedlinePlus: Betaxolol Ophthalmic Information

Common questions about Бетофтан (FAQ)

Q: How quickly does Бетофтан start working after use?

A: According to official product information, the medicine is described as beginning its action, which is a reduction in intraocular pressure, within approximately 30 minutes following topical administration. The maximum reduction in pressure is generally seen within two hours of use.

Q: What is the expected duration of the effects of Бетофтан?

A: Regulatory information indicates that a single dose of the solution is expected to provide a sustained reduction in elevated intraocular pressure that lasts for around 12 hours. This duration relates to the control of intraocular pressure, which is maintained through a consistent dosing schedule.

Q: What makes Бетофтан different from other medicines that treat similar conditions?

A: Official documents define this medicine as a cardioselective beta1-adrenergic receptor blocking agent, meaning it primarily targets the beta1 receptors in the eye that control fluid. The beta1-selectivity is a characteristic that distinguishes it from non-selective beta-blockers, which may have a broader effect on beta2 receptors, including those in the lungs.

Q: Is it normal to feel a stinging sensation when using Бетофтан?

A: Yes, regulatory safety information documents that transient ocular discomfort and a burning sensation upon instillation are among the most frequently reported (very common) adverse reactions. Regulatory documents describe this discomfort as transient.

Q: Can Бетофтан cause vision changes or blurry sight?

A: Official safety labeling notes that blurred vision and other temporary visual disturbances are commonly reported adverse reactions. These temporary visual effects are described as common adverse reactions.

Q: Is hair loss a possible side effect of Бетофтан, even though it's an eye drop?

A: Although the medicine is applied locally to the eye, its active ingredient is absorbed into the bloodstream. Official reports of systemic effects include hair loss (alopecia) among the documented, though uncommon, adverse reactions.

Q: Can I use Бетофтан if I'm taking blood pressure medication?

A: Regulatory labeling cautions that combining this medicine with oral beta-blockers, calcium channel blockers, or other drugs affecting heart rhythm or blood pressure may result in additive effects. These effects could include low blood pressure (hypotension) or slow heart rate (bradycardia). The potential for these additive effects is a factor that necessitates careful monitoring.

Q: Are there any specific supplements or vitamins that might interact with Бетофтан?

A: Official information mentions that the medicine may interact with some oral vitamin and mineral supplements. Furthermore, regulatory information indicates that consultation regarding the use of herbal products is a necessary precaution.

Q: Can I use Бетофтан for a condition not listed in the official uses?

A: The medicine has been approved and labeled by regulatory agencies specifically for the treatment of open-angle glaucoma and ocular hypertension. Regulatory documents provide no information regarding the use of the drug for any conditions outside of its approved indications.

Q: Is Бетофтан suitable for people with diabetes?

A: Official warnings note that the drug may be used with caution in patients with diabetes. beta-blockers can potentially mask the physical signs of acute hypoglycemia (low blood sugar), such as a fast or pounding heartbeat.

Q: What does the research say about Бетофтан's effectiveness?

A: Clinical studies consistently indicate that the medicine is effective in achieving a lowering of intraocular pressure (IOP), which is the primary measured goal of the therapy. However, existing research provides limited data on the long-term changes to functional visual outcomes reflecting daily life.

Q: What is the official information regarding driving or operating heavy machinery while using Бетофтан?

A: Official guidance advises caution because temporary effects such as blurred vision or other visual disturbances may occur immediately after using the drops. Therefore, the official guidance indicates that individuals should not drive or operate machinery until the visual disturbance has resolved.

Q: Why do some people report headaches after starting Бетофтан?

A: Headache is officially listed as a common adverse reaction that has been reported by patients using the medicine. However, the regulatory documents do not provide a specific physiological explanation for why this effect occurs.

Q: Does Бетофтан contain any preservatives that could cause irritation?

A: Yes, the solution contains the common preservative benzalkonium chloride (BAK) as one of its inactive ingredients. This substance is known to potentially cause eye irritation and is also the reason contact lenses must be removed before use.

Q: Does Бетофтан affect tear production?

A: Official reports of adverse reactions include both increased lacrimation (more tearing) and dry eyes among the documented ocular effects. This indicates that the medicine may influence the tear film or production mechanisms in some patients.

Q: Has Бетофтан been studied in long-term safety trials?

A: Research has included long-term observational studies with follow-up periods lasting up to several years that tracked the consistency of intraocular pressure changes and examined overall safety patterns.

Q: What are the official warnings for people with liver or kidney problems using Бетофтан?

A: Official documents note that the drug is primarily eliminated from the body through liver metabolism and kidney excretion. Because of this elimination pathway, caution is noted for patients with severe renal (kidney) impairment, although the ophthalmic solution is only minimally absorbed.

Q: Is there a generic version of Бетофтан available?

A: Information regarding the use of the active ingredient, betaxolol, in prescription drug markets suggests that a generic version of the ophthalmic solution is commonly available in various formulations.

Q: What does the official information say about overdose with Бетофтан?

A: Official information warns that accidental ingestion or excessive topical use could lead to systemic absorption effects similar to taking beta-blocker pills. These effects may include dangerously slow heart rate (bradycardia), very low blood pressure (hypotension), and potentially breathing difficulties (bronchospasm).

How to Store and Dispose of Betophtan (Betaxolol Ophthalmic Solution)

Official regulatory information mandates specific conditions to maintain the stability and sterility of Betophtan (Betaxolol ophthalmic solution).

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, between 15 C to 30 C (59 F to 86 F).
Protection	Keep from freezing and protect from excessive heat, moisture, and direct light.
Container	The container must be kept tightly closed when not in use. Avoid contaminating the dropper tip.
Safety	Store the medicine out of the reach of children and pets.

Disposal Instructions

Betophtan should not be used past the expiration date or if it has been frozen. Some product labels specify discarding the solution 4 weeks after opening. Unused or expired medication should be disposed of via an authorized drug take-back program. If no program is available, the product must be mixed with an undesirable substance (such as dirt) and placed in a sealed container before disposal in the household trash. Do not dispose of by flushing down the toilet or drain.